作者：
Selen, Arzu [1]
;
Dickinson, Paul A. [2]
;
Mullertz, Anette [3]
;
Crison, John R. [4]
;
Mistry, Hitesh B. [5]
;
Cruanes, Maria T. [6]
;
Martinez, Marilyn N. [7]
;
Lennernas, Hans [8]
;
Wigal, Tim L. [9]
;
Swinney, David C. [10]
;
Polli, James E. [11]
;
Serajuddin, Abu T. M. [12]
;
Cook, Jack A. [13]
;
Dressman, Jennifer B. [14]
作者单位：
AstraZeneca, Quantitat Clin Pharmacol, Macclesfield, Cheshire, England
[1]
Uppsala Univ, Dept Pharm, Uppsala, Sweden
[2]
St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY USA
[3]
Bristol Myers Squibb Co, New Brunswick, NJ USA
[4]
Goethe Univ Frankfurt, Bioctr, Inst Pharmaceut Technol, D-60054 Frankfurt, Germany
[5]
Univ Calif Irvine, Child Dev Ctr, Irvine, CA USA
[6]
US FDA CVM, Rockville, MD USA
[7]
Univ Copenhagen, Fac Pharmaceut Sci, Copenhagen, Denmark
[8]
Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[9]
iRND3, Mountain View, CA USA
[10]
Merck & Co Inc, West Point, PA USA
[11]
Physiomics PLC, Oxford, England
[12]
Pfizer Inc, Groton, CT 06340 USA
[13]
US FDA, Off New Drug Qual Assessment, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
[14]
发布时间
2015-10-13
换一批
